Digital Defocus Vision Training (DDVT) System Development and Application

January 2, 2026 updated by: Jin Yuan, Zhongshan Ophthalmic Center, Sun Yat-sen University

Development of Digital Defocus Vision Training (DDVT) System Based on Virtual Reality Technology and Its Application in Myopia Regulation

Myopia is the first major disease affecting the visual health of young children. With the increase in the use of electronic products and the decrease in the time for outdoor exercise, the incidence of myopia is increasing year by year. Smith et al. firstly found that peripheral retinal defocus affects the course of myopia development in rhesus monkeys. Subsequent studies have shown that peripheral retinal hyperopic defocus can lead to the growth of the axial length (AL), leading to the development of myopia, while peripheral retinal myopic defocus can effectively slow down the growth of the AL, thus delaying the progression of myopia. Defocus signals can simultaneously change the thickness of the choroid, the vascular tissue behind the retina, and the pigment epithelium, and change the thickness and hardness of the sclera, inhibiting or promoting the growth of the axial length. Therefore, many methods have been designed to intervene in the development of myopia, including orthokeratology and peripheral defocusing glasses. The maintenance process of orthokeratology lens is complex and there is a risk of infection. Peripheral defocus glasses need to be worn for a long time, and the visual quality is unstable. It is still necessary to explore safer, more effective and more practical methods for myopia control. In addition, there may be some correlation between the development of myopia and the decrease of choroidal blood flow. Defocus signal may promote the increase of choroidal blood flow, which may be a way to prevent and control myopia.

Therefore, the investigators integrated the digital defocus paradigm into VR devices and developed a digital defocus vision training (DDVT) system. The purpose of this study was to investigate the effectiveness and safety of DDVT in the prevention and control of myopia in children.

Study Overview

Study Type

Interventional

Enrollment (Actual)

116

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beijing, China, 100730
        • Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing Tongren Eye Center
    • Guangdong
      • Guangzhou, Guangdong, China, 510060
        • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen Universit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • children aged 6 to 12 years
  • diagnosis of myopia with SER of -0.75 to -6.00 D
  • regular astigmatism, and astigmatism less than 2.50D
  • anisometropia less than 1.50 D
  • a logMAR best-corrected visual acuity (BCVA) of 0.00 or better
  • an understanding by participants and their legal guardians of the purpose of the study

Exclusion Criteria:

  • other myopia control therapies in the last 6 months (including but not limited to atropine and orthokeratology)
  • strabismus, amblyopia, congenital lens dislocation, congenital cataract, glaucoma, uveitis, nystagmus, keratoconus, eye neoplasms and other ocular diseases
  • systemic diseases such as nephrotic syndrome or diabetes
  • structural changes in the eyeball, a history of ocular surgery or trauma
  • other systemic diseases affecting eye health
  • participants in other clinical trials at the same time.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DDVT training group
During a six-month follow-up period, participants received 10 minutes of DDVT twice a day (once in the morning, and the other in the afternoon) using a head-mounted virtual reality (VR) display. In daily life during non-training sessions, participants were required to wear frame glasses with complete correction.
During a six-month follow-up period, participants received 10 minutes of DDVT twice a day (once in the morning, and the other in the afternoon) using a head-mounted VR display. In daily life during non-training sessions, participants were required to wear frame glasses with complete correction.
No Intervention: control group
The control group did not have any myopia prevention and control intervention in half a year, and only wore complete-corrected frame glasses in daily life

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the axial length (AL)
Time Frame: 1 year
The axial length of the eye is the distance from the anterior surface of the cornea to the posterior surface of the retina. In a normal adult, it is approximately 24 mm , and its growth is closely related to myopia . AL was measured using the IOL Master (Carl Zeiss 500, Meditec, Oberkochen, Germany)
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
spherical equivalent refraction
Time Frame: 1 year
Then used 0.5% tropicamide, five minutes apart, to perform three cycloplegia. The pupil is not considered fully dilated until it is larger than 6mm and/or has no light reflex. Autorefraction was measured in each eye using the Topcon KR-8800 (Topcon, Tokyo, Japan). Cycloplegic spherical equivalent refraction (SER) was defined as the spherical degree plus half of the cylindrical degree.
1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Negative relative accommodation
Time Frame: 1 year
Negative relative accommodation (NRA) refers to the degree of relaxation of the eye's accommodation ability when the convergence is fixed. It is one of the important indicators for evaluating binocular visual function. NRA was measured using the Topcon CV-5000 (Topcon, Tokyo, Japan)
1 year
Positive relative accommodation
Time Frame: 1 year
Positive relative accommodation (PRA) refers to the ability of energy regulation to increase when the convergence remains unchanged in the binocular fixation state. It is used to evaluate the accommodative reserve capacity of patients。 PRA was measured using the Topcon CV-5000 (Topcon, Tokyo, Japan)
1 year
The accommodation facility
Time Frame: 1 year
The accommodation facility refers to the ability of the eye to adjust its state quickly as needed, which in the field of vision is expressed as ciliary muscle accommodation speed. The accommodation facility was measured using a ± 2.0 D flipper lens; IOP was measured using the Topcon CT-1 (Topcon, Tokyo, Japan).
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2024

Primary Completion (Actual)

October 1, 2025

Study Completion (Actual)

October 8, 2025

Study Registration Dates

First Submitted

June 7, 2025

First Submitted That Met QC Criteria

June 18, 2025

First Posted (Actual)

June 27, 2025

Study Record Updates

Last Update Posted (Actual)

January 6, 2026

Last Update Submitted That Met QC Criteria

January 2, 2026

Last Verified

June 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 2023KYPJ282

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Virtual Reality Therapy

Clinical Trials on Development of digital defocus vision training (DDVT)

3
Subscribe